Verdamicin is a new aminoglycoside antibiotic isolated from fermentation broths of a species of the genus Micromonospora, M. grisea. It has been differentiated from other known related antibiotics by a variety of chemical and biological methods. Its in vitro and in vivo spectrum of activity appears to be similar to those of gentamicin and sisomicin.
Several species of Micromonospora, M. purpurea, M. echinospora, M. inyoensis, and M. spp. 69-683 have previously been described by our laboratory to produce, respectively, the aminoglycoside antibiotics gentamicins, (3), sisomicin, (4), as well as a known streptomycete-produced antibiotic, neomycin (2) . In this report we present initial data on a novel aminoglycoside antibiotic named verdamicin, which is produced by a species of Micromonospora, M. grisea. Preliminary results concerning the producing organism as well as chemical and biological characteristics of verdamicin are presented. MATERIALS Fermentation conditions. For laboratory production of verdamicin, a loopful of M. grisea from an agar slant or 0.5 ml of a frozen whole preparation was used to inoculate each of a series of 300-ml Erlenmeyer flasks containing 100 ml of the inoculum media (Table 1) . The flasks and their contents were incubated for 3 days at 35 C on a rotary shaker. Five milliliters of inoculum were transferred to 500-ml Erlenmeyer flasks containing 100 ml of the fermentation medium (Table 1 ). The fermentations were carried out at 26 to 35 C for 4 to 7 days with continual agitation on a rotary shaker at 200 to 350 rpm.
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Microbiological assay. Antibiotic potencies were determined by means of a disk plate assay with Staphylococcus aureus ATCC 6538P as the test organism. The physical conditions of the assay are similar to those described for gentamicin (1) . After separation of components as will be described, the verdamicin standard was established. A unit of verdamicin activity is the amount of antibiotic which produces a zonal response of 17.0 i 1.3 mm under the conditions of the assay and by definition is equal to 1 jg. Antibiotic isolation. Verdamicin was isolated from an antibiotic mixture found in the fermentation broth by a cation exchange procedure. The pH was adjusted to 2 with mineral acid to release the major portion of the antibiotic from the mycelium. The broth was filtered, neutralized, and adsorbed to an IRC 50 (NH4+) ion exchange resin column. The antibiotic mixture was eluted from the resin with 2 N ammonium hydroxide. Separation and isolation of the components was achieved by silica gel chromatography with the lower phase of a solvent mixture consisting of chloroform, isopropanol, and concentrated ammonium hydroxide (2:1:1 vol/vol).
Chromatographic methods. Chromatographic comparisons of a variety of antibiotics were carried out by development on Whatman no. 1 paper in the solvent systems shown in Table 2 . The following antibiotics were used in their sulfate forms: verdamicin complex, sisomicin, gentamicin Cl, C2, C,a (Schering Corporation, Bloomfield, N.J.), neomycin (Upjohn Co., Kalmazoo, Mich.), kanamycin (Bristol Laboratories, Syracuse, N.Y.), paromomycin (ParkeDavis and Co., Detroit, Mich.), and tobramycin (Eli Lilly and Co., Indianapolis, Ind.).
Hydrolysis of antibiotics. All antibiotics were hydrolyzed for comparative purposes as the free bases, sulfate and N-acetyl derivatives (10 mg/ml) in 6 N hydrochloric acid in sealed tubes at 100 C for 2 h.
In vitro studies. For determination of in vitro sensitivity, all test organisms were incubated in Mueller-Hinton broth, pH 7.4, at 37 C for 18 to 24 h except when otherwise indicated. The volume in each tube was 3 ml, and the inoculum was 0.05 ml of a 1:1,000 dilution of an 18-h broth culture.
In vivo studies. Animal for verdamicin, sisomicin, and gentamicin against a group of sensitive Escherichia coli strains. All three antibiotics lacked activity against two E. coli strains containing the gentamicin adenylylating R-factor, but showed good activity against an E. coli strain carrying an R-factor responsible for tobramycin resistance. Similar potencies were observed against a group of Proteus, Salmonella, and Klebsiella strains. None of the antibiotics was very active against a Klebsiella strain containing the gentamicin adenylylating R-factor, but all three were highly active against a strain carrying the kanamycinphosphorylating R-factor. Against several resistant Pseudomonas strains, the three antibiotics appeared to be cross-resistant, as evidenced by the lack of activity, or poor activity, against gentamicin-resistant strains and comparable activity against gentamicin-susceptible strains. that verdamicin is 2 to 3 times more active than gentamicin or tobramycin against gram-positive organisms, and 1.5 to over 3 times more active against gram-negative organisms, with the exception of Pseudomonas. Verdamicin has slightly greater activity against Pseudomonas than does gentamicin, and somewhat less activity than does tobramycin. Verdamicin was slightly more active against gram-positive bacteria than sisomicin and was approximately as active as sisomicin against gram-negative bacteria except for Pseudomonas. Thus, as noted with in vitro data, verdamicin lies between gentamicin and tobramycin on one hand, and sisomicin on the other, in respect to potency against E. coli, Proteus sp. and P. aeruginosa.
In other studies against a small number of organisms, minimal bactericidal concentration levels were not greatly different than minimal inhibitory concentration (static) levels in common with related aminoglycosides. Initial estimates of serum binding suggest it is low, as is the case with gentamicin and sisomicin.
The comparative acute toxicity of these antibiotics is shown in Table 6 . As noted with the protective activity, the acute toxicity of verdamicin in mice more closely relates to that of sisomicin than to either gentamicin or tobramycin.
Verdami6in was shown to be substantially less ataxic in cats than gentamicin, producing ataxia in 26 days, as compared to 16 days for gentamicin at a dosage of 40 mg/kg, 7 days per week. 
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